Antibody studies were performed from time of delivery using both the discarded clinical maternal peripheral blood samples and the corresponding discarded clinical neonatal umbilical cord blood samples.
Immunoglobulin G (IgG) antibodies against SARS-CoV-2 were assayed using a fluorescence-based reporting system which allows for semi-quantitative detection of anti-SARS-CoV-2 spike antibodies using the clinical testing Pylon 3D platform (ET HealthCare, Palo Alto, CA). This platform utilizes a fluorescence-based reporting system which allows for semi-quantitative detection of anti-SARS-CoV-2 IgG with a specificity of 98.8%. Anti-Nucleocapsid (anti-N) antibodies were also measured with the Elecsys Anti-SARS-CoV-2 assay (Roche) to assess evidence of past SARS-CoV-2 infection. IgG levels were plotted as log2 + 116 (link),39 (link).
Immunoglobulin G (IgG) antibodies against SARS-CoV-2 were assayed using a fluorescence-based reporting system which allows for semi-quantitative detection of anti-SARS-CoV-2 spike antibodies using the clinical testing Pylon 3D platform (ET HealthCare, Palo Alto, CA). This platform utilizes a fluorescence-based reporting system which allows for semi-quantitative detection of anti-SARS-CoV-2 IgG with a specificity of 98.8%. Anti-Nucleocapsid (anti-N) antibodies were also measured with the Elecsys Anti-SARS-CoV-2 assay (Roche) to assess evidence of past SARS-CoV-2 infection. IgG levels were plotted as log2 + 116 (link),39 (link).
Free full text: Click here
